| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Elevance Health (NYSE:ELV) has been analyzed by 16 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 11 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 4 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 4 | 6 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $605.69, a high estimate of $649.00, and a low estimate of $557.00. Surpassing the previous average price target of $590.17, the current average has increased by 2.63%.
The standing of Elevance Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Erin Wright | Morgan Stanley | Announces | Overweight | $643.00 | - |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $600.00 | $600.00 |
| Scott Fidel | Stephens & Co. | Maintains | Overweight | $615.00 | $615.00 |
| Kevin Fischbeck | B of A Securities | Raises | Buy | $646.00 | $621.00 |
| Lisa Gill | JP Morgan | Raises | Overweight | $631.00 | $628.00 |
| Michael Ha | Baird | Announces | Outperform | $649.00 | - |
| Ann Hynes | Mizuho | Raises | Buy | $585.00 | $575.00 |
| Ben Hendrix | RBC Capital | Raises | Outperform | $575.00 | $574.00 |
| A.J. Rice | UBS | Raises | Buy | $605.00 | $585.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $600.00 | $557.00 |
| David Macdonald | Truist Securities | Raises | Buy | $600.00 | $580.00 |
| David Windley | Jefferies | Raises | Buy | $604.00 | $602.00 |
| Andrew Mok | Barclays | Raises | Overweight | $621.00 | $584.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $580.00 | - |
| Stephen Baxter | Wells Fargo | Lowers | Overweight | $557.00 | $561.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $580.00 | - |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Elevance Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Elevance Health analyst ratings.
Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Elevance Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.96% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.28%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Elevance Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.62% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Elevance Health's ROA stands out, surpassing industry averages. With an impressive ROA of 2.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Elevance Health's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.65, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ELV
